Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: Predictions of compounds as precipitants of interaction

Drug Metabolism and Disposition

Volumn 37, Issue 8, 2009, Pages 1658-1666

  Fahmi, Odette A ^a   Hurst, Susan ^a   Plowchalk, David ^a   Cook, Jack ^a   Guo, Feng ^a   Youdim, Kuresh ^b   Dickins, Maurice ^b   Phipps, Alex ^b   Darekar, Amanda ^b   Hyland, Ruth ^b   Obach, R Scott ^a  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; ATORVASTATIN; AZITHROMYCIN; CARBAMAZEPINE; CHLORZOXAZONE; CIMETIDINE; CLARITHROMYCIN; CONIVAPTAN; CYTOCHROME P450 3A4; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; FLUMAZENIL; FLUOXETINE; FLUVOXAMINE; GATIFLOXACIN; ITRACONAZOLE; KETOCONAZOLE; MIBEFRADIL; MIDAZOLAM; NEFAZODONE; NITRENDIPINE; PARECOXIB; RANITIDINE; RIFAMPICIN; ROXITHROMYCIN; SAQUINAVIR; TROLEANDOMYCIN; UNINDEXED DRUG; VERAPAMIL;

ALGORITHM; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INTERACTION; DRUG METABOLISM; HUMAN; INTESTINE; LIVER; MATHEMATICAL MODEL; PRIORITY JOURNAL;

ALGORITHMS; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS; INTESTINES; LIVER; MIDAZOLAM; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 67650825002     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.026252     Document Type: Article

References (39)

1. Bachmann KA and Lewis JD (2005) Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 39:1064-1072.
2. Berthou F, Goasduff T, Lucas D, Dréano Y, Le Bot MH, and Ménez JF (1995) Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogenetics 5:72-79.
3. i, IC50 and inhibitor concentration. Curr Drug Metab 5:147-156.
4. Brown HS, Galetin A, Hallifax D, and Houston JB (2006) Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45:1035-1050.
5. Chien JY, Lucksiri A, Ernest CS 2nd, Gorski JC, Wrighton SA, and Hall SD (2006) Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos 34:1208-1219.
6. Einolf HJ (2007) Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37:1257-1294.
7. Ernest CS 2nd, Hall SD, and Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583-591.
8. Fahmi OA, Boldt S, Kish M, Obach RS, and Tremaine LM (2008a) Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dispos 36:1971-1974.
9. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, and Nettleton D (2008b) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698-1708.
10. Galetin A, Burt H, Gibbons L, and Houston JB (2006) Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166-175.
11. Galetin A, Gertz M, and Houston JB (2008) Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 4:909-922.
12. Galetin A, Hinton LK, Burt H, Obach RS, and Houston JB (2007) Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 8:685-693.
13. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
14. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, and Rostami-Hodjegan A (2009) The Simcyp® population-Based ADME Simulator. Expert Opin Drug Metab Toxicol doi: 10.1517/17425250802691074.
15. Kanamitsu S, Ito K, and Sugiyama Y (2000a) Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 17:336-343.
16. Kanamitsu SI, Ito K, Okuda H, Ogura K, Watabe T, Muro K, and Sugiyama Y (2000b) Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl)uracil. Drug Metab Dispos 28:467-474.
17. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037.
18. McGinnity DF, Berry AJ, Kenny JR, Grime K, and Riley RJ (2006) Evaluation of timedependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 34:1291-1300.
19. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, and Kliewer SA (2000) St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 97:7500-7502.
20. Obach RS (2000) Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 294:88-95.
21. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255.
22. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
23. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, and Tremaine LM (2005) In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78:582-592.
24. Ohno Y, Hisaka A, Ueno M, and Suzuki H (2008) General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet 47:669-680.
25. Palmer JL, Scott RJ, Gibson A, Dickins M, and Pleasance S (2001) An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br J Clin Pharmacol 52:555-561.
26. Riley RJ, Grime K, and Weaver R (2007) Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3:51-66.
27. Rostami-Hodjegan A and Tucker GT (2004) 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov Today: Technol 1:441-448.
28. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148.
29. Sauer JM, Long AJ, Ring B, Gillespie JS, Sanburn NP, DeSante KA, Petullo D, VandenBranden MR, Jensen CB, Wrighton SA, et al. (2004) Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther 308:410-418.
30. Shou M, Hayashi M, Pan Y, Xu Y, Morrissey K, Xu L, and Skiles GL (2008) Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos 36:2355-2370.
31. Sinz M, Kim S, Zhu Z, Chen T, Anthony M, Dickinson K, and Rodrigues AD (2006) Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375-388.
32. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
33. Tucker GT, Houston JB, and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res 18:1071-1080.
34. Venkatakrishnan K and Obach RS (2007) Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 8:449-462.
35. Venkatakrishnan K, von Moltke LL, Obach RS, and Greenblatt DJ (2003) Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 4:423-459.
36. Veronese ML, Gillen LP, Dorval EP, Hauck WW, Waldman SA, and Greenberg HE (2003) Effect of mibefradil on CYP3A4 in vivo. J Clin Pharmacol 43:1091-1100.
37. Wang YH, Jones DR, and Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-266.
38. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2008) Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9:384-394.
39. Zhou SF (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310-322.